Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Joice Huang"'
Autor:
William R. Lenderking, Huamao Lin, Rebecca M. Speck, David Kerstein, Joice Huang, Corey J Langer, Yanyan Zhu, Hui Huang
Publikováno v:
Future Oncology. 15:2841-2855
Aim: Patient-reported outcomes (PRO) can support clinically relevant primary end points. Materials & methods: The ALTA trial, an open-label, Phase II, randomized dose-comparison study, evaluated the safety and efficacy of brigatinib in ALK+ non-small
Autor:
William R. Lenderking, Joice Huang, Pingkuan Zhang, Hui Huang, David Kerstein, Ariane K. Kawata, Huamao M. Lin, Olabimpe R. Eseyin
Publikováno v:
Journal of Medical Economics. 22:924-935
Aims: Health utilities summarize a patient’s overall health status. This study estimated utilities based on the European Organization for Research and Treatment of Cancer Quality of Life Qu...
Autor:
Andrés Redondo, Laurie Eliason, Rebecca Kristeleit, Jubilee Brown, Joice Huang, Cara Mathews, Ellie Im
Publikováno v:
Endometrial cancer.
Introduction/Background PROs enable direct measurement of the experiences of pts with cancer related to an intervention. Regulators increasingly use PROs to inform the risks and benefits of new drug candidates, focusing on 3 core concepts: physical f
Autor:
Andrés Redondo, Cara Mathews, Jubilee Brown, Joice Huang, Rebecca Kristeleit, Laurie Eliason, Ellie Im
Publikováno v:
Journal of Clinical Oncology. 38:275-275
275 Background: PRO enable direct measurement of the experiences of patients with cancer. Anti-programmed death 1 (PD-1) therapies have shown favorable PRO in lung cancer but a data gap remains in EC. Dostarlimab is an investigational anti-PD-1 monoc
Autor:
Ellie Im, Andrés Redondo, Rebecca Kristeleit, Laurie Eliason, C. Matthews, Jubilee Brown, Joice Huang
Publikováno v:
Annals of Oncology. 31:S637
Publikováno v:
Journal of Clinical Oncology. 38:e18036-e18036
274 Background: Patient (pt) prognosis is poor following disease progression on or after primary (1L) platinum-based therapy (PBT) for advanced/recurrent (A/R) endometrial cancer (EC), and no consensus on standard second-line (2L) therapy exists. Thi
Autor:
Cara Mathews, Andrés Redondo, Ellie Im, Rebecca Kristeleit, Jubilee Brown, Joice Huang, Laurie Eliason
Publikováno v:
Journal of Clinical Oncology. 38:e18032-e18032
e18032 Background: PRO enable direct measurement of the experiences of patients with cancer. Anti-programmed death 1 (PD-1) therapies have shown favorable PRO in lung cancer but a data gap remains in EC. Dostarlimab is an investigational anti-PD-1 mo
Autor:
Joice Huang, Irina Proskorovsky, Stanimira Krotneva, Huamao M. Lin, Hui Huang, Joseph W. Y. Lee, William Reichmann, David Kerstein, Karen L. Reckamp
Objective: Brigatinib, ceritinib, and alectinib are approved to treat crizotinib-refractory anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC), but no trial has compared them head-to-head. A matching-adjusted indirect compa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e256651f60e808b13b4740f58cc48a44
Autor:
Primal Kaur, En-Tzu Tang, Alfred H. Moffett, Sacha Satram-Hoang, Rachel B. Wagman, Joice Huang, Rob Horne, D. Macarios, David L. Kendler, M. Lillestol
Publikováno v:
Menopause. 21:25-32
This study aims to evaluate patient perceptions of subcutaneous denosumab or oral alendronate in postmenopausal women with or at risk for osteoporosis and how these perceptions influence adherence.Postmenopausal women with low bone mass were randomiz
Autor:
Morgan Kruse, Anju Parthan, Hema N. Viswanathan, Nicole Yurgin, Douglas C.A. Taylor, Joice Huang
Publikováno v:
Applied Health Economics and Health Policy. 11:485-497
In the US, 26 % of women aged ≥65 years, and over 50 % of women aged ≥85 years are affected with postmenopausal osteoporosis (PMO). Each year, the total direct health care costs are estimated to be $US12–18 billion. The cost effectiveness of de